Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Head and Neck Squamous Cell Cancer
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
The selection of treatment for lip and oral cavity cancer depends on the site and extent of the primary tumor and the status of the lymph nodes. Some options for treatment of this cancer include:[1-5]
Surgery alone.
Radiation therapy alone.
A combination of the surgery and radiation therapy.
For lesions of the oral cavity, surgery must adequately encompass all of the gross as well as the presumed microscopic extent of the disease. If regional nodes are positive, cervical node dissection is usually done in continuity. With modern approaches, the surgeon can successfully ablate large posterior oral cavity tumors and with reconstructive methods can achieve satisfactory functional results. Prosthodontic rehabilitation is important, particularly in early-stage cancers, to assure the best quality of life.
Radiation therapy for lip and oral cavity cancers can be given by external-beam radiation therapy (EBRT) or interstitial implantation alone, but for many sites the use of both modalities produces better control and functional results. Small superficial cancers can be very successfully treated by local implantation using any one of several radioactive sources, by intraoral cone radiation therapy, or by electrons. Larger lesions are frequently managed using EBRT to include the primary site and regional lymph nodes, even if they are not clinically involved. Supplementation with interstitial radiation sources may be necessary to achieve adequate doses to large primary tumors and/or bulky nodal metastases. A review of published clinical results of radical radiation therapy for head and neck cancer suggests a significant loss of local control with prolonged radiation therapy; therefore, lengthened standard treatment schedules should be avoided whenever possible.[6,7]
Early cancers (stage I and stage II) of the lip, floor of the mouth, and retromolar trigone are highly curable by surgery or radiation therapy. The choice of treatment is dictated by the anticipated functional and cosmetic results. Availability of a surgeon or radiation oncologist with the required expertise for the individual patient is also a factor in treatment choice.
Advanced cancers (stage III and stage IV) of the lip, floor of the mouth, and retromolar trigone represent a wide spectrum of challenges for the surgeon and radiation oncologists. Most patients with stage III or stage IV tumors are candidates for treatment with a combination of surgery and radiation therapy. The exceptions are patients with small T3 lesions and no regional lymph nodes, and no distant metastases or patients who have no lymph nodes larger than 2 cm in diameter, for whom treatment by radiation therapy alone or surgery alone might be appropriate. Because local recurrence and/or distant metastases are common in this group of patients, clinical trials that are evaluating the following should be considered:
The potential role of radiation modifiers to improve local control or decrease morbidity.
The role of combinations of chemotherapy with surgery and/or radiation therapy to improve local control and to decrease the frequency of distant metastases.
Early cancers of the buccal mucosa are equally curable by radiation therapy or adequate excision. Patient factors and local expertise influence the choice of treatment. Larger cancers require composite resection with reconstruction of the defect by pedicle flaps.
Early lesions (T1 and T2) of the anterior tongue may be managed by surgery or by radiation therapy alone. Both modalities produce 70% to 85% cure rates in patients with early lesions. Moderate excisions of tongue, even hemiglossectomy, can often result in little speech disability provided the wound closure is such that the tongue is not bound down. However, if the resection is more extensive, problems may include aspiration of liquids and solids, difficulty swallowing, and speech difficulties. Occasionally, patients with tumor of the tongue require almost total glossectomy. Large lesions generally require combined surgical and radiation treatment. The control rates for larger lesions are about 30% to 40%. According to clinical and radiological evidence of involvement, cancers of the lower gingiva that are exophytic and amenable to adequate local excision may be excised to include portions of bone. More advanced lesions require segmental bone resection, hemimandibulectomy, or maxillectomy, depending on the extent of the lesion and its location.
Early lesions of the upper gingiva or hard palate without bone involvement can be treated with equal effectiveness by surgery or radiation therapy alone. Advanced infiltrative and ulcerating lesions should be treated by a combination of radiation therapy and surgery. Most primary cancers of the hard palate are of minor salivary gland origin. Primary squamous cell carcinoma of the hard palate is uncommon, and these tumors generally represent invasion of squamous cell carcinoma arising on the upper gingiva, which is much more common. Management of squamous cell carcinoma of the upper gingiva and hard palate is usually considered together. Surgical treatment of cancer of the hard palate usually requires excision of underlying bone producing an opening into the antrum. This defect can be filled and covered with a dental prosthesis, which is a maneuver that restores satisfactory swallowing and speech.
Patients who smoke while receiving radiation therapy appear to have lower response rates and shorter survival durations than those who do not;[8] therefore, patients should be counseled to stop smoking before beginning radiation therapy. Dental status evaluation should be performed prior to therapy to prevent late sequelae.
Sources: 8
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[9,10] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[9-11] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[12-14] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[15] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[16]
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage I small lesions of the lip include:
Surgery.
Radiation therapy.
Surgery and radiation therapy produce similar cure rates, and the method of treatment is dictated by the anticipated cosmetic and functional results.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage I small anterior tongue lesions include:
Wide local excision is often used for small lesions that can be resected transorally.
For patients with larger T1 lesions, the following standard treatments are used:
For patients with larger T1 lesions, the following standard treatments are used:
Surgery.
Radiation therapy.
Interstitial implantation alone or with external-beam radiation therapy.
Irradiation of the neck.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage I small lesions of the buccal mucosa include:
Surgery alone for patients with lesions smaller than 1 cm in diameter, if the commissure is not involved.
Radiation therapy, including brachytherapy, should be considered to treat lesions smaller than 1 cm in diameter, if the commissure is involved.
Surgical excision with a split-thickness skin graft or radiation therapy is used to treat larger T1 lesions.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage I small lesions of the floor of the mouth include:
Surgery for patients with T1 lesions.
Radiation therapy is used to treat T1 lesions.
Excision alone is generally adequate to treat lesions smaller than 0.5 cm if there is a margin of normal mucosa between the lesion and the gingiva.
Surgery is often used if the lesion is attached to the periosteum.
Radiation therapy is often used if the lesion encroaches on the tongue.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage I small lesions of the lower gingiva include:
Intraoral resection with or without a rim resection of bone and repair with a split-thickness skin graft are used to treat small lesions.
Radiation therapy may be used for small lesions, but results are generally better after surgery alone.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage I small tumors of the retromolar trigone include:
Limited resection of the mandible is performed for early lesions without detectable bone invasion.
Radiation therapy may be used initially if limited resection is not feasible, with surgery reserved for radiation failure.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage I small lesions of the upper gingiva and hard palate include:
Surgical resection is used to treat most small lesions.
Postoperative radiation therapy may be used if appropriate.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Surgery and/or radiation therapy may be used, depending on the exact site.[1]
Sources: 1
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage II small lesions of the lip include:
Surgery is used for patients with smaller T2 lesions on the lower lip, if simple closure produces an acceptable cosmetic result.
Radiation therapy, which may include external-beam and/or interstitial techniques, as appropriate, has the advantage of producing a relatively better functional and cosmetic result, with intact skin and muscle innervation, if a reconstructive surgical procedure is required.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage II small anterior tongue lesions include:
Radiation therapy is usually selected for patients with T2 lesions that have minimal infiltration to preserve speech and swallowing.[2]
Sources: 2
Surgery is reserved for patients for whom radiation treatment failed.[2]
Sources: 2
Neck dissection may be considered when primary brachytherapy is used.[2]
Sources: 2
Surgery, radiation therapy, or a combination of both are used for deeply infiltrative lesions.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage II small lesions of the buccal mucosa include:
Radiation therapy is the usual treatment for patients with small T2 lesions (≤3 cm).
Surgery, radiation therapy, or a combination of these are used, if indicated to treat large T2 lesions (>3 cm). Radiation therapy is often used if the lesion involves the commissure. Surgery is often used, if tumor invades the mandible or maxilla.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage II small lesions of the floor of the mouth include:
Surgery is often used for patients with small T2 lesions (≤3 cm) if the lesion is attached to the periosteum.
Radiation therapy is often used to treat patients with small T2 lesions (≤3 cm) if the lesion encroaches on the tongue.
Surgery and radiation therapy are alternative methods of treatment for patients with large T2 lesions (>3 cm), the choice of which depends primarily on the expected extent of disability from surgery.
External-beam radiation therapy with or without interstitial radiation therapy should be considered postoperatively for larger lesions.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage II small lesions of the lower gingiva include:
Intraoral resection with or without a rim resection of bone and repair with a split-thickness skin graft are used to treat patients with small lesions.
Radiation therapy may be used to treat patients with small lesions, but results are generally better after surgery alone.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage II small tumors of the retromolar trigone include:
Limited resection of the mandible is performed to treat patients with early lesions that are without detectable bone invasion.
Radiation therapy may be used initially if limited resection is not feasible.
Surgery is reserved for radiation failure.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage II small lesions of the upper gingiva and hard palate include:
Surgical resection with postoperative radiation therapy, as appropriate, is used to treat most lesions. A small study showed that radiation therapy may be used effectively as the sole treatment modality.[3]
Sources: 3
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Surgery and/or radiation therapy are used, depending on the exact tumor site.[1,2] Neoadjuvant chemotherapy, as given in clinical trials, has been used to shrink tumors and render them more definitively treatable with either surgery or radiation. Neoadjuvant chemotherapy is given prior to the other modalities, as opposed to standard adjuvant chemotherapy, which is given after or during definitive therapy with radiation or after surgery. Many drug combinations have been used as neoadjuvant chemotherapy.[3-6] However, randomized, prospective trials have yet to demonstrate a benefit in either disease-free survival or overall survival for patients receiving neoadjuvant chemotherapy.[7]
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
These lesions, including those involving bone, nerves, and lymph nodes, generally require a combination of surgery and radiation therapy.
Treatment options for stage III advanced lesions of the lip include:
Surgery using a variety of approaches, the choice of which is dependent on the size and location of the lesion and the need for reconstruction.
Radiation therapy using a variety of techniques, including external-beam radiation therapy (EBRT) with or without brachytherapy, the choice of which is dictated by the size and location of the lesion.
Clinical trials for advanced tumors evaluating the use of chemotherapy preoperatively, before radiation therapy, as adjuvant therapy after surgery, or as part of combined modality therapy are appropriate.[3-6,8-10]
Superfractionated radiation therapy (under clinical evaluation).[11]
Sources: 11
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage III moderately advanced (late T2, small T3) lesions of the anterior tongue include:
EBRT with or without interstitial implant is used to treat minimally infiltrative lesions.
Surgery with postoperative radiation therapy is used to treat deeply infiltrative lesions.[2]
Sources: 2
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage III advanced lesions of the buccal mucosa include:
Radical surgical resection alone.
Radiation therapy alone.
Surgical resection plus radiation therapy, generally postoperative.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage III moderately advanced lesions of the floor of the mouth include:
Surgery using rim resection plus neck dissection or partial mandibulectomy with neck dissection, as appropriate.
Radiation therapy using EBRT alone or EBRT plus an interstitial implant.
Clinical trials for advanced tumors evaluating the use of chemotherapy preoperatively, before radiation therapy, as adjuvant therapy after surgery, or as part of combined modality therapy are appropriate.[3-6,8-10,12]
Clinical trials using novel radiation therapy fractionation schemas.[13]
Sources: 13
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage III moderately advanced lesions of the lower gingiva include:
Combined radiation therapy and radical resection or radical resection alone are used to treat extensive lesions with moderate bone destruction and/or nodal metastases. Radiation therapy may be administered either preoperatively or postoperatively.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage III advanced lesions of the retromolar trigone include:
Surgical composite resection, which may be followed by postoperative radiation therapy.
Clinical trials for advanced tumors evaluating the use of chemotherapy preoperatively, before radiation therapy, as adjuvant therapy after surgery, or as part of combined modality therapy are appropriate.[3-6,8-10,12]
Clinical trials using novel radiation therapy fractionation schemas.[13]
Sources: 13
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage III moderately advanced lesions of the upper gingiva include:
Radiation therapy alone is used to treat superficial lesions with extensive involvement of the gingiva, hard palate, or soft palate.
A combination of surgery and radiation therapy is used to treat deeply invasive lesions involving bone.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage III moderately advanced lesions of the hard palate include:
Radiation therapy alone is used to treat superficial lesions with extensive involvement of the gingiva, hard palate, or soft palate.
A combination of surgery and radiation therapy or surgery alone is used to treat deeply invasive lesions involving bone.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Chemotherapy has been combined with radiation therapy in patients who have locally advanced disease that is surgically unresectable.[8,10,14,15]A meta-analysis of 63 randomized prospective trials published between 1965 and 1993 showed an 8% absolute survival advantage in the subset of patients who received concurrent chemotherapy and radiation therapy.[16][Level of evidence B4] Patients who received adjuvant or neoadjuvant chemotherapy had no survival advantage. Cost, quality of life, and morbidity data were not available. No standard regimen existed, and the trials were felt to be too heterogenous to provide definitive recommendations. The results of 18 ongoing trials may further clarify the role of concurrent chemotherapy and radiation therapy in the management of oral cavity cancer.The best chemotherapy to use and the appropriate way to integrate the two modalities is still unresolved.[17]Similar approaches in the patient with resectable disease, in whom resection would lead to a major functional deficit, are also being explored in randomized trials but cannot be recommended at this time as standard.
Clinical trials of novel fractionation radiation therapy are under evaluation.[13]
Sources: 13
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Randomized prospective trials have yet to demonstrate a benefit in either disease-free survival or overall survival for patients receiving neoadjuvant chemotherapy.[1] The use of isotretinoin daily for 1 year to prevent development of second upper aerodigestive tract primaries is under clinical evaluation.[2]
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
These lesions, including those involving bone, nerves, and lymph nodes, generally require a combination of surgery and radiation therapy.
Treatment options for stage IV advanced lesions of the lip include:
Surgery using a variety of approaches, the choice of which is dependent on the size and location of the lesion and the need for reconstruction. Treatment of both sides of the neck is indicated for selected patients.
Radiation therapy using a variety of techniques, including external-beam radiation therapy (EBRT) with or without brachytherapy, the choice of which is dictated by the size and location of the lesion.
Superfractionated radiation therapy (under clinical evaluation).[3]
Sources: 3
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage IV advanced lesions of the anterior tongue include:
Combined surgery (i.e., total glossectomy, sometimes requiring laryngectomy), possibly followed by postoperative radiation therapy, may be used to treat selected patients.[4]
Sources: 4
Palliative radiation therapy may be used to treat patients with very advanced lesions.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage IV advanced lesions of the buccal mucosa include:
Radical surgical resection alone.
Radiation therapy alone.
Surgical resection plus radiation therapy, which is generally administered postoperatively.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage IV advanced lesions of the floor of the mouth include:
A combination of surgery and radiation therapy, which is generally administered postoperatively, is often used.
Preoperative radiation therapy is often used for fixed nodes (≥5 cm).
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage IV advanced lesions of the lower gingiva include:
Surgery, radiation therapy, or a combination of both are poor controls for advanced tumors with extensive destruction of the mandible and with nodal metastases.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage IV advanced lesions of the retromolar trigone include:
Surgical composite resection followed by postoperative radiation therapy.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage IV advanced lesions of the upper gingiva include:
Surgery in combination with radiation therapy is generally used to treat lesions that are extensive and infiltrating.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for stage IV advanced lesions of the hard palate include:
Surgery in combination with radiation therapy is generally used to treat lesions that are extensive and infiltrating.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Chemotherapy has been combined with radiation therapy in patients who have locally advanced disease that is surgically unresectable.[5-8]A meta-analysis of 63 randomized prospective trials published between 1965 and 1993 showed an 8% absolute survival advantage in the subset of patients who received concurrent chemotherapy and radiation therapy.[9][Level of evidence B4] Patients who received adjuvant or neoadjuvant chemotherapy had no survival advantage. Cost, quality of life, and morbidity data were not available. No standard regimen existed, and the trials were felt to be too heterogenous to provide definitive recommendations. The results of 18 ongoing trials may further clarify the role of concurrent chemotherapy and radiation therapy in the management of oral cavity cancer. The best chemotherapy to use and the appropriate way to integrate the two modalities is still unresolved.[10]Similar approaches in the patient with resectable disease, in whom resection would lead to a major functional deficit, are also being explored in randomized trials but cannot be recommended at this time as standard.
Sources: 5 · 8 · 9 · Level of evidence B4 · 10
Clinical trials for advanced tumors evaluating the use of chemotherapy preoperatively, before radiation therapy, or as adjuvant therapy after surgery are appropriate.[5,11-18]
Clinical trials of novel fractionation radiation therapy are under evaluation.[19]
Sources: 19
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Patients with advanced lesions should have elective lymph node radiation therapy or node dissection. The risk of metastases to lymph nodes is increased by high-grade histology, large lesions, spread to involve the wet mucosa of the lip or the buccal mucosa in patients with recurrent disease, and invasion of muscle (i.e., orbicularis oris).[1]
Sources: 1
Treatment options for management of lymph node metastases include:
Radiation therapy alone or neck dissection:
Radiation therapy alone or neck dissection:
N1 (0–2 cm).
N2b or N3; all nodes smaller than 2 cm. (A combined surgical and radiation therapy approach should also be considered.)
Radiation therapy and neck dissection:
Radiation therapy and neck dissection:
N1 (2–3 cm), N2a, N3.
Surgery followed by radiation therapy, indications for which are as follows:
Surgery followed by radiation therapy, indications for which are as follows:
Multiple positive nodes.
Contralateral subclinical metastases.
Invasion of tumor through the capsule of the lymph node.
N2b or N3 (one or more nodes in each side of the neck, as appropriate, >2 cm).
Radiation therapy prior to surgery:
Radiation therapy prior to surgery:
Large fixed nodes.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for metastatic and recurrent lip and oral cavity cancer include:
Surgery is the preferred treatment if radiation therapy was used initially.[3]
Sources: 3
Surgery,[3] radiation therapy, or a combination of these treatments may be considered if surgery was used to treat the lesion initially.
Sources: 3
Immunotherapy.[4-12]
Sources: Immunotherapy · 4 · 12
Nivolumab.
Sources: Nivolumab
Although chemotherapy has been shown to induce responses, no increase in survival has been demonstrated.[13]
Sources: 13
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Pembrolizumab is a monoclonal antibody and an inhibitor of the programmed death-1 (PD-1) pathway. Studies have evaluated pembrolizumab in patients with incurable metastatic or recurrent head and neck squamous cell carcinoma (SCC).
Evidence (pembrolizumab as first-line therapy):
KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[6] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population.
Sources: KEYNOTE-048 · 6
KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[6] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population.
At the second interim analysis, pembrolizumab alone showed improved or noninferior OS compared with cetuximab with chemotherapy. The median OS results were reported as follows:[6][Level of evidence A1]
Sources: 6 · Level of evidence A1
KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[6] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population. › At the second interim analysis, pembrolizumab alone showed improved or noninferior OS compared with cetuximab with chemotherapy. The median OS results were reported as follows:[6][Level of evidence A1]
Among the population with a CPS of 20 or higher, the median OS was 14.9 months in patients who received pembrolizumab alone and 10.7 months in patients who received cetuximab with chemotherapy (hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.45–0.83; P = .0007).
Among the population with a CPS of 1 or higher, the median OS was 12.3 months in patients who received pembrolizumab alone and 10.3 months in patients who received cetuximab with chemotherapy (HR, 0.78; 95% CI, 0.64–0.96; P = .0086).
Among the total population, patients who received pembrolizumab alone had noninferior OS (11.6 months) compared with patients who received cetuximab with chemotherapy (10.7 months) (HR, 0.85; 95% CI, 0.71–1.03; P = .0456).
KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[6] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population.
Pembrolizumab with chemotherapy showed improved OS versus cetuximab with chemotherapy. The OS results were reported as follows:
KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[6] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population. › Pembrolizumab with chemotherapy showed improved OS versus cetuximab with chemotherapy. The OS results were reported as follows:
At the second interim analysis, among the total population, the median OS was 13.0 months in patients who received pembrolizumab with chemotherapy and 10.7 months in patients who received cetuximab with chemotherapy (HR, 0.77; 95% CI, 0.63–0.93; P = .0034).
At the final analysis, among the population with a CPS of 20 or higher, the median OS was 14.7 months in patients who received pembrolizumab with chemotherapy and 11.0 months in patients who received cetuximab with chemotherapy (HR, 0.60; 95% CI, 0.45–0.82; P = .0004).
At the final analysis, among the population with a CPS of 1 or higher, the median OS was 13.6 months in patients who received pembrolizumab with chemotherapy and 10.4 months in patients who received cetuximab with chemotherapy (HR, 0.65; 95% CI, 0.53–0.80; P < .0001).
KEYNOTE-048 (NCT02358031) was a nonblinded, randomized, phase III study of participants with untreated locally incurable metastatic or recurrent head and neck SCC that was performed at 200 sites in 37 countries.[6] A total of 882 patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab alone (n = 301), pembrolizumab plus a platinum and fluorouracil (5-FU) (pembrolizumab with chemotherapy) (n = 281), or cetuximab plus a platinum and 5-FU (cetuximab with chemotherapy) (n = 300). Investigators, patients, and representatives of the sponsor were masked to the programmed death-ligand 1 (PD-L1) combined positive score (CPS) results; PD-L1 positivity was not required for study entry. A total of 754 patients (85%) had a CPS of 1 or higher and 381 patients (43%) had a CPS of 20 or higher.The primary end points were overall survival (OS) and progression-free survival (PFS). Progression was defined as radiographically confirmed disease progression or death from any cause, whichever came first, in the intention-to-treat population.
At the second interim analysis, neither pembrolizumab alone nor pembrolizumab with chemotherapy improved PFS.
At the final analysis, grade 3 or higher all-cause adverse events occurred in 164 of 300 patients (55%) in the pembrolizumab-alone group, 235 of 276 patients (85%) who received pembrolizumab with chemotherapy, and 239 of 287 patients (83%) who received cetuximab with chemotherapy.
Adverse events led to death in 25 patients (8%) in the pembrolizumab-alone group, 32 patients (12%) who received pembrolizumab with chemotherapy, and 28 patients (10%) who received cetuximab with chemotherapy.
Pembrolizumab plus a platinum and 5-FU is an appropriate first-line treatment for patients with metastatic or recurrent head and neck SCC. Pembrolizumab monotherapy is an appropriate first-line treatment for patients with PD-L1–positive metastatic or recurrent head and neck SCC. These results were confirmed at a longer median follow-up of 45 months (interquartile range, 41.0–49.2).[7]
Sources: 7
Evidence (pembrolizumab after progression on platinum-based treatment):
The phase III KEYNOTE-040 (NCT02252042) trial included patients with incurable metastatic or recurrent head and neck SCC who had received platinum-based treatment within 3 to 6 months.[4] Patients were randomly assigned to the pembrolizumab arm (200 mg every 3 weeks [247 patients]) or to the standard therapy arm of the investigator’s choice (methotrexate, docetaxel, or cetuximab [248 patients]). Patients received treatment until progression or toxicity. The maximum duration of pembrolizumab was 24 months. The primary end point was OS in the intention-to-treat population.
Sources: KEYNOTE-040 · 4
The phase III KEYNOTE-040 (NCT02252042) trial included patients with incurable metastatic or recurrent head and neck SCC who had received platinum-based treatment within 3 to 6 months.[4] Patients were randomly assigned to the pembrolizumab arm (200 mg every 3 weeks [247 patients]) or to the standard therapy arm of the investigator’s choice (methotrexate, docetaxel, or cetuximab [248 patients]). Patients received treatment until progression or toxicity. The maximum duration of pembrolizumab was 24 months. The primary end point was OS in the intention-to-treat population.
The median OS was 8.4 months in the pembrolizumab arm and 6.9 months in the standard therapy arm (HR, 0.80; 95% CI, 0.65–0.98; nominal P = .0161).[4][Level of evidence A1]
Sources: 4 · Level of evidence A1
Pembrolizumab was associated with fewer grade 3 or higher adverse events (pembrolizumab, 13% vs. standard therapy, 36%). The most common treatment-related adverse events were hypothyroidism (13%) in the pembrolizumab arm and fatigue (18%) in the standard therapy arm.
In patients who received pembrolizumab, there were four treatment-related deaths resulting from large intestinal perforation, Stevens-Johnson syndrome, and unspecified malignant progression. Two treatment-related deaths in the standard therapy arm resulted from malignant progression and pneumonia.
The PD-L1 CPS was 1 or higher in 79% of the patients in the pembrolizumab arm and 77% of the patients in the standard therapy arm.
Compared with patients treated with standard therapy, a reduced HRdeath was noted for patients who received pembrolizumab and had PD-1 expression on their tumors or in the tumor microenvironment as noted by a PD-L1 CPS of 1 or higher (HR, 0.74; 95% CI, 0.58–0.93; nominal P = .0049) or a PD-L1 tumor proportion score of 50% or higher (HR, 0.53; 95% CI, 0.35–0.81; nominal P = .0014).
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Nivolumab is a fully human immunoglobulin G4 anti–PD-1 monoclonal antibody.
Evidence (nivolumab combined with ipilimumab in patients who have not previously received systemic therapy):
The CheckMate 651 trial (NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab, cisplatin/carboplatin, and 5-FU for up to six cycles followed by cetuximab maintenance) in patients with recurrent or metastatic head and neck SCC.[9] The primary end points were OS in all randomly assigned patients and patients with a PD-L1 CPS of 20 or higher. Secondary end points included OS in patients with a PD-L1 CPS of 1 or higher and PFS, objective response rate, and duration of response in all randomly assigned patients and patients with a PD-L1 CPS of 20 or higher. The absence of a survival benefit for immune checkpoint inhibitors in this trial was an unexpected outcome, given the similarity of nivolumab to pembrolizumab in the studies of patients with cisplatin-refractory disease.[4,5] An editorial accompanying the CheckMate 651 trial analyzed some of the factors that may have contributed to a different result. The editorial suggested that survival in the control group, which was longer than that reported in prior studies, may have been impacted by the greater availability of second-line immunotherapy in the control group (46% in CheckMate 651 compared with 25% in the KEYNOTE-048 trial). The authors also suggested that the coadministration of ipilimumab detracted from the activity of nivolumab, as shown in the CheckMate 714 trial.[8]
Sources: CheckMate 651 · 9 · 4 · 5 · 8
The CheckMate 651 trial (NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab, cisplatin/carboplatin, and 5-FU for up to six cycles followed by cetuximab maintenance) in patients with recurrent or metastatic head and neck SCC.[9] The primary end points were OS in all randomly assigned patients and patients with a PD-L1 CPS of 20 or higher. Secondary end points included OS in patients with a PD-L1 CPS of 1 or higher and PFS, objective response rate, and duration of response in all randomly assigned patients and patients with a PD-L1 CPS of 20 or higher. The absence of a survival benefit for immune checkpoint inhibitors in this trial was an unexpected outcome, given the similarity of nivolumab to pembrolizumab in the studies of patients with cisplatin-refractory disease.[4,5] An editorial accompanying the CheckMate 651 trial analyzed some of the factors that may have contributed to a different result. The editorial suggested that survival in the control group, which was longer than that reported in prior studies, may have been impacted by the greater availability of second-line immunotherapy in the control group (46% in CheckMate 651 compared with 25% in the KEYNOTE-048 trial). The authors also suggested that the coadministration of ipilimumab detracted from the activity of nivolumab, as shown in the CheckMate 714 trial.[8]
Among all randomly assigned patients, there was no statistically significant difference in OS with nivolumab plus ipilimumab versus EXTREME (median OS, 13.9 vs. 13.5 months; HR, 0.95; 97.9% CI, 0.80–1.13; P = .4951). Among patients with a PD-L1 CPS of 20 or higher, there was also no statistically significant OS difference between the two treatments (median OS, 17.6 vs. 14.6 months; HR, 0.78; 97.51% CI, 0.59–1.03; P = .0469).[9][Level of evidence A1]
Sources: 9 · Level of evidence A1
In patients with a CPS of 1 or higher, the median OS was 15.7 months for patients who received nivolumab plus ipilimumab versus 13.2 months for patients who received EXTREME (HR, 0.82; 95% CI, 0.69–0.97).
Among patients with a CPS of 20 or higher, the median PFS was 5.4 months for patients who received nivolumab plus ipilimumab and 7.0 months for patients who received EXTREME. The objective response rate was 34.1% for patients who received nivolumab plus ipilimumab and 36.0% for patients who received EXTREME.
Grade 3 or 4 treatment-related adverse events occurred in 28.2% of patients who received nivolumab plus ipilimumab and 70.7% of patients who received EXTREME.
CheckMate 651 did not meet its primary end points of OS in the randomly assigned or CPS of 20 or higher populations.
CheckMate 714 (NCT02823574), a double-blind phase II trial, evaluated the clinical benefit of first-line nivolumab plus ipilimumab versus nivolumab alone in 425 patients with recurrent or metastatic head and neck SCC.[10] Patients were randomly assigned in a 2:1 ratio to receive either nivolumab (3 mg/kg intravenously [IV] every 2 weeks) plus ipilimumab (1 mg/kg IV every 6 weeks) or nivolumab (3 mg/kg IV every 2 weeks) plus placebo. Treatment continued for up to 2 years or until disease progression, unacceptable toxic effects, or consent withdrawal. The primary end points were objective response rate and duration of response between treatment arms by blinded independent central review in the population with platinum-refractory recurrent or metastatic disease. These were patients who had recurrent disease less than 6 months after completion of platinum-based chemotherapy (adjuvant or neoadjuvant, or as part of multimodal treatment [chemotherapy, surgery, and/or radiation therapy]). Among the 241 patients (56.7%) with platinum-refractory disease, 159 were assigned to receive nivolumab plus ipilimumab and 82 were assigned to receive nivolumab alone. Among the 184 patients (43.3%) with platinum-eligible disease, 123 were assigned to receive nivolumab plus ipilimumab and 61 were assigned to receive nivolumab alone.[10][Level of evidence B3]
Sources: CheckMate 714 · 10 · 10 · Level of evidence B3
CheckMate 714 (NCT02823574), a double-blind phase II trial, evaluated the clinical benefit of first-line nivolumab plus ipilimumab versus nivolumab alone in 425 patients with recurrent or metastatic head and neck SCC.[10] Patients were randomly assigned in a 2:1 ratio to receive either nivolumab (3 mg/kg intravenously [IV] every 2 weeks) plus ipilimumab (1 mg/kg IV every 6 weeks) or nivolumab (3 mg/kg IV every 2 weeks) plus placebo. Treatment continued for up to 2 years or until disease progression, unacceptable toxic effects, or consent withdrawal. The primary end points were objective response rate and duration of response between treatment arms by blinded independent central review in the population with platinum-refractory recurrent or metastatic disease. These were patients who had recurrent disease less than 6 months after completion of platinum-based chemotherapy (adjuvant or neoadjuvant, or as part of multimodal treatment [chemotherapy, surgery, and/or radiation therapy]). Among the 241 patients (56.7%) with platinum-refractory disease, 159 were assigned to receive nivolumab plus ipilimumab and 82 were assigned to receive nivolumab alone. Among the 184 patients (43.3%) with platinum-eligible disease, 123 were assigned to receive nivolumab plus ipilimumab and 61 were assigned to receive nivolumab alone.[10][Level of evidence B3]
At primary database lock, the objective response rate in the population with platinum-refractory disease was 13.2% (95% CI, 8.4%–19.5%) with nivolumab plus ipilimumab and 18.3% (95% CI, 10.6%–28.4%) with nivolumab alone (odds ratio, 0.68; 95.5% CI, 0.33–1.43; P = .29).
The median duration of response was not reached (NR) in the nivolumab-plus-ipilimumab group (95% CI, 11.0 months–NR) and was 11.1 months (95% CI, 4.1–NR) in the nivolumab-alone group. In the population with platinum-eligible disease, the objective response rate was 20.3% (95% CI, 13.6%–28.5%) with nivolumab plus ipilimumab and 29.5% (95% CI, 18.5%–42.6%) with nivolumab alone.
Among the population with platinum-refractory disease, grade 3 or 4 treatment-related adverse events occurred in 25 of 158 patients (15.8%) who received nivolumab plus ipilimumab and in 12 of 82 patients (14.6%) who received nivolumab alone. Among the population with platinum-eligible disease, grade 3 or 4 treatment-related adverse events occurred in 30 of 122 patients (24.6%) who received nivolumab plus ipilimumab and in 8 of 61 patients (13.1%) who received nivolumab alone.
This trial did not meet its primary end point of objective response rate benefit with first-line nivolumab plus ipilimumab versus nivolumab alone in patients with platinum-refractory recurrent or metastatic head and neck SCC.
Evidence (nivolumab after progression on platinum-based treatment):
A phase III open-label trial included 361 patients with recurrent SCC of the head and neck and disease progression within 6 months after platinum-based chemotherapy. Patients were randomly assigned in a 2:1 ratio to receive either nivolumab (at a dose of 3 mg/kg of body weight) every 2 weeks or standard single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary end point was OS.[5]
Sources: 5
A phase III open-label trial included 361 patients with recurrent SCC of the head and neck and disease progression within 6 months after platinum-based chemotherapy. Patients were randomly assigned in a 2:1 ratio to receive either nivolumab (at a dose of 3 mg/kg of body weight) every 2 weeks or standard single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary end point was OS.[5]
The median OS was 7.5 months (95% CI, 5.5–9.1) in the nivolumab group versus 5.1 months (95% CI, 4.0–6.0) in the standard therapy group. OS was statistically significantly longer with nivolumab than with standard therapy (HRdeath, 0.70; 97.73% CI, 0.51–0.96; P = .01). The estimated 1-year survival rate was approximately 19% higher in patients who received nivolumab (36.0%) than in those who received standard therapy (16.6%).[5][Level of evidence A1]
Sources: 5 · Level of evidence A1
There was no statistically significant difference in median PFS between treatment groups. The 6-month PFS rate was 19.7% with nivolumab versus 9.9% with standard therapy.
The response rate was 13.3% in the nivolumab group versus 5.8% in the standard therapy group.
Grade 3 or 4 treatment-related adverse events occurred in 13.1% of the patients in the nivolumab group compared with 35.1% of the patients in the standard therapy group.
Quality-of-life outcomes—including physical, role, and social functioning and pain, sensory, and social contact problems—were stable in the nivolumab group but worse in the standard therapy group. These outcomes were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core Module (QLQ-C30) and the Head and Neck Module (QLQ-H&N35).
In the subgroup of patients with a PD-L1 expression level of 1% or higher, the HRdeath among patients treated with nivolumab versus standard therapy was 0.55 (95% CI, 0.36–0.83). In the subgroup of patients with a PD-L1 expression level lower than 1%, the HR was 0.89 (95% CI, 0.54–1.45; P = .17 for interaction).
A randomized, phase III, superiority study in India evaluated the dose of immune checkpoint inhibitors in the setting of palliative care for patients with advanced head and neck cancer. Low-dose IV nivolumab (20 mg every 3 weeks) was added to a triple metronomic chemotherapy regimen of oral methotrexate (9 mg/m2 once weekly), celecoxib (200 mg twice daily), and erlotinib (150 mg once daily). Notably, this nivolumab dose is less than 10% of the dose recommended by the U.S. Food and Drug Administration and the European Medicines Agency. A total of 151 patients were randomly assigned to receive either triple metronomic chemotherapy alone (n = 75) or triple metronomic chemotherapy with nivolumab (n = 76). The primary end point was 1-year OS.[11]Although the control arm in this study cannot be considered standard care, lower doses of immunotherapy appeared to have some benefit in this setting.[12]
A randomized, phase III, superiority study in India evaluated the dose of immune checkpoint inhibitors in the setting of palliative care for patients with advanced head and neck cancer. Low-dose IV nivolumab (20 mg every 3 weeks) was added to a triple metronomic chemotherapy regimen of oral methotrexate (9 mg/m2 once weekly), celecoxib (200 mg twice daily), and erlotinib (150 mg once daily). Notably, this nivolumab dose is less than 10% of the dose recommended by the U.S. Food and Drug Administration and the European Medicines Agency. A total of 151 patients were randomly assigned to receive either triple metronomic chemotherapy alone (n = 75) or triple metronomic chemotherapy with nivolumab (n = 76). The primary end point was 1-year OS.[11]Although the control arm in this study cannot be considered standard care, lower doses of immunotherapy appeared to have some benefit in this setting.[12]
The addition of low-dose nivolumab to triple metronomic chemotherapy improved the 1-year OS rate from 16.3% (95% CI, 8.0%–27.4%) to 43.4% (95% CI, 30.8%–55.3%) (HR, 0.545; 95% CI, 0.362–0.820; P = .0036).[11][Level of evidence A1]
Sources: 11 · Level of evidence A1
The median OS was 6.7 months (95% CI, 5.8–8.1) for patients who received triple metronomic chemotherapy alone and 10.1 months (95% CI, 7.4–12.6) for patients who received triple metronomic chemotherapy with nivolumab (P = .0052).
The rate of grade 3 or higher adverse events was 50% for patients who received triple metronomic chemotherapy alone and 46.1% for patients who received triple metronomic chemotherapy with nivolumab (P = .744).
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
The prognosis depends on:
Sources: prognosis
the cancer stage
Sources: stage
where the tumor is in the lip or oral cavity
whether the cancer has spread to blood vessels
Sources: blood vessels
For patients who smoke, the chance of recovery is better if they stop smoking before beginning radiation therapy.
Sources: radiation therapy
Treatment options depend on:
the stage of the cancer
the size of the tumor and where it is in the lip or oral cavity
whether the patient's appearance and ability to talk and eat can stay the same
the patient's age and general health
Patients who have had lip and oral cavity cancer have an increased risk of developing a second cancer in the head or neck. Frequent and careful follow-up is important. Clinical trials are studying the use of retinoid drugs to reduce the risk of a second head and neck cancer. Information about ongoing clinical trials is available from the NCI website.
Sources: second cancer · follow-up · Clinical trials · retinoid · NCI website
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Recurrent lip and oral cavity cancer is cancer that has come back after it has been treated. If lip and oral cavity cancer comes back, it may come back in the lip, mouth, or other parts of the body. Tests will help determine where in the body the cancer has returned. The type of treatment that you have for recurrent lip and oral cavity cancer will depend on where it has come back.
Learn more in Recurrent Cancer: When Cancer Comes Back.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
There are different types of treatment for people with lip and oral cavity cancer.
People with lip and oral cavity cancer should have their treatment planned by a team of doctors who are expert in treating head and neck cancer.
The following types of treatment are used:
The following types of treatment are used:
Surgery
Radiation therapy
Immunotherapy
New types of treatment are being tested in clinical trials.
Follow-up care may be needed.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Different types of treatments are available for lip and oral cavity cancer. You and your cancer care team will work together to decide your treatment plan, which may include more than one type of treatment. Many factors will be considered, such as the stage of the cancer, your overall health, and your preferences. Your plan will include information about your cancer, the goals of treatment, your treatment options and the possible side effects, and the expected length of treatment.
Talking with your cancer care team before treatment begins about what to expect will be helpful. You'll want to learn what you need to do before treatment begins, how you'll feel while going through it, and what kind of help you will need. Learn more at Questions to Ask Your Doctor About Treatment.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
An oncologist, a doctor who specializes in treating people with cancer, oversees treatment for lip and oral cavity cancer. Because the lips and oral cavity are important for breathing, eating, and talking, you may need special help adjusting to the side effects of the cancer and its treatment. The oncologist may refer you to other health care providers who are experts in treating head and neck cancer and also specialize in other areas of medicine. Other specialists may include:
Sources: oral cavity · side effects · head and neck cancer
head and neck surgeon
Sources: surgeon
radiation oncologist
Sources: radiation oncologist
dentist
Sources: dentist
speech therapist
Sources: speech therapist
dietitian
Sources: dietitian
psychologist
Sources: psychologist
rehabilitation specialist
Sources: rehabilitation specialist
plastic surgeon
Sources: plastic surgeon
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Surgery (removing the cancer in an operation) is a common treatment for all stages of lip and oral cavity cancer. Surgery may include:
Sources: stages
Wide local excision is the removal of the cancer and some of the healthy tissue around it. If cancer has spread into bone, surgery may include removal of the involved bone tissue.
Sources: Wide local excision
Neck dissection is the removal of lymph nodes and other tissues in the neck. This is done when cancer may have spread from the lip and oral cavity.
Sources: lymph nodes
Plastic surgery is an operation that restores or improves the appearance of parts of the body. Dental implants, a skin graft, or other plastic surgery may be needed to repair parts of the mouth, throat, or neck after removal of large tumors.
Sources: Dental implants · skin graft · throat
After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.
Sources: chemotherapy · radiation therapy · adjuvant therapy
Learn more about Surgery to Treat Cancer.
Sources: Surgery to Treat Cancer
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing by damaging their DNA. External and internal radiation therapy are used to treat lip and oral cavity cancer:
External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.
Internal radiation therapy (also called brachytherapy) uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.
Sources: Internal radiation therapy · radioactive · seeds · catheters
Radiation therapy may work better in patients who have stopped smoking before beginning treatment. It is also important for patients to have a dental exam before radiation therapy begins so that existing problems can be treated.
Learn more about Radiation Therapy to Treat Cancer and Radiation Therapy Side Effects.
Sources: Radiation Therapy to Treat Cancer · Radiation Therapy Side Effects
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Immunotherapy helps a person’s immune system fight cancer. Your doctor may suggest biomarker tests to help predict your response to certain immunotherapy drugs. Learn more about Biomarker Testing for Cancer Treatment.
Sources: biomarker tests · Biomarker Testing for Cancer Treatment
Immunotherapy drugs used to treat squamous cell carcinoma of the lip and oral cavity cancer that has come back or spread to other parts of the body include:
Sources: squamous cell carcinoma
nivolumab
Sources: nivolumab
pembrolizumab
Sources: pembrolizumab
Learn more about Immunotherapy to Treat Cancer.
Sources: Immunotherapy to Treat Cancer
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using existing treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials that are accepting participants. This search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn the basics about clinical trials at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Learn about the treatments listed below in the Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of stage I lip and oral cavity cancer depends on where cancer is found in the lip and oral cavity.
Sources: stage I lip and oral cavity cancer
Lip
If cancer is in the lip, treatment may include:
surgery (wide local excision)
Sources: wide local excision
internal radiation therapy with or without external radiation therapy
Sources: internal radiation therapy · external radiation therapy
Front of the tongue
If cancer is in the front of the tongue, treatment may include:
surgery (wide local excision)
Sources: wide local excision
internal radiation therapy with or without external radiation therapy
Sources: internal radiation therapy · external radiation therapy
radiation therapy to lymph nodes in the neck
Sources: radiation therapy · lymph nodes
Buccal mucosa
If cancer is in the buccal mucosa (the lining of the inside of the cheeks), treatment may include:
surgery (wide local excision) for tumors smaller than 1 centimeter, with or without internal and/or external radiation therapy
Sources: wide local excision · centimeter · internal · external radiation therapy
surgery (wide local excision with skin graft) or radiation therapy for larger tumors
Sources: skin graft · radiation therapy
Floor of the mouth
If cancer is in the floor (bottom) of the mouth, treatment may include:
surgery (wide local excision) for tumors smaller than ½ centimeter
Sources: wide local excision · centimeter
surgery (wide local excision) or radiation therapy for larger tumors
Sources: radiation therapy
Lower gingiva
If cancer is in the lower gingiva (gums), treatment may include:
Sources: gingiva
surgery (wide local excision, which may include removing part of the jawbone, and skin graft)
Sources: wide local excision · skin graft
radiation therapy with or without surgery
Sources: radiation therapy
Retromolar trigone
If cancer is in the retromolar trigone (the small area behind the wisdom teeth), treatment may include:
Sources: retromolar trigone · wisdom teeth
surgery (wide local excision, which may include removing part of the jawbone)
Sources: wide local excision
radiation therapy with or without surgery
Sources: radiation therapy
Upper gingiva or hard palate
If cancer is in the upper gingiva (gums) or the hard palate (the roof of the mouth), treatment is usually surgery (wide local excision) with or without radiation therapy.
Sources: gingiva · hard palate · wide local excision · radiation therapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Learn about the treatments listed below in the Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of stage II lip and oral cavity cancer depends on where cancer is found in the lip and oral cavity.
Sources: stage II lip and oral cavity cancer
Lip
If cancer is in the lip, treatment may include:
surgery (wide local excision)
Sources: wide local excision
external radiation therapy and/or internal radiation therapy
Sources: external radiation therapy · internal radiation therapy
Front of the tongue
If cancer is in the front of the tongue, treatment may include:
radiation therapy and/or surgery (wide local excision)
Sources: radiation therapy · wide local excision
internal radiation therapy with surgery (neck dissection)
Sources: internal radiation therapy · neck dissection
Buccal mucosa
If cancer is in the buccal mucosa (the lining of the inside of the cheeks), treatment may include:
Sources: buccal mucosa
radiation therapy for tumors that are 3 centimeters or smaller
Sources: radiation therapy · centimeters
surgery (wide local excision) and/or radiation therapy for larger tumors
Sources: wide local excision
Floor of the mouth
If cancer is in the floor (bottom) of the mouth, treatment may include:
surgery (wide local excision)
Sources: wide local excision
radiation therapy
Sources: radiation therapy
surgery (wide local excision) followed by external radiation therapy, with or without internal radiation therapy, for large tumors
Sources: external radiation therapy · internal radiation therapy
Lower gingiva
If cancer is in the lower gingiva (gums), treatment may include:
Sources: gingiva
surgery (wide local excision, which may include removing part of the jawbone, and a skin graft)
Sources: wide local excision · skin graft
radiation therapy alone or after surgery
Sources: radiation therapy
Retromolar trigone
If cancer is in the retromolar trigone (the small area behind the wisdom teeth), treatment may include:
Sources: retromolar trigone · wisdom teeth
surgery (wide local excision, which includes removing part of the jawbone)
Sources: wide local excision
radiation therapy with or without surgery
Sources: radiation therapy
Upper gingiva or hard palate
If cancer is in the upper gingiva (gums) or the hard palate (the roof of the mouth), treatment may include:
Sources: gingiva · hard palate
surgery (wide local excision) with or without radiation therapy
Sources: wide local excision · radiation therapy
radiation therapy alone
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Learn about the treatments listed below in the Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of stage III lip and oral cavity cancer depends on where cancer is found in the lip and oral cavity.
Sources: stage III lip and oral cavity cancer
Lip
If cancer is in the lip, treatment may include surgery and external radiation therapy with or without internal radiation therapy.
Sources: external radiation therapy · internal radiation therapy
Front of the tongue
If cancer is in the front of the tongue, treatment may include:
external radiation therapy with or without internal radiation therapy
Sources: external radiation therapy · internal radiation therapy
surgery (wide local excision) followed by radiation therapy
Sources: wide local excision · radiation therapy
Buccal mucosa
If cancer is in the buccal mucosa (the lining of the inside of the cheeks), treatment may include:
Sources: buccal mucosa
surgery (wide local excision) with or without radiation therapy
Sources: wide local excision · radiation therapy
radiation therapy
Floor of the mouth
If cancer is in the floor (bottom) of the mouth, treatment may include:
surgery (wide local excision, which may include removing part of the jawbone, with or without neck dissection)
Sources: wide local excision · neck dissection
external radiation therapy with or without internal radiation therapy
Sources: external radiation therapy · internal radiation therapy
Lower gingiva
If cancer is in the lower gingiva (gums), treatment may include surgery (wide local excision) with or without radiation therapy. Radiation may be given before or after surgery.
Sources: gingiva · wide local excision · radiation therapy
Retromolar trigone
If cancer is in the retromolar trigone (the small area behind the wisdom teeth), treatment may include surgery to remove the tumor, lymph nodes, and part of the jawbone, with or without radiation therapy.
Sources: retromolar trigone · wisdom teeth · lymph nodes · radiation therapy
Upper gingiva
If cancer is in the upper gingiva (gums), treatment may include:
Sources: gingiva
radiation therapy
Sources: radiation therapy
surgery (wide local excision) and radiation therapy
Sources: wide local excision
Hard palate
If cancer is in the hard palate (the roof of the mouth), treatment may include:
Sources: hard palate
radiation therapy
Sources: radiation therapy
surgery (wide local excision) with or without radiation therapy
Sources: wide local excision
Lymph nodes
For cancer that may have spread to lymph nodes, treatment may include radiation therapy and/or surgery (neck dissection).
Sources: lymph nodes · radiation therapy · neck dissection
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Learn about the treatments listed below in the Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of stages IVA and IVB lip and oral cavity cancer depends on where cancer is found in the lip and oral cavity.
Sources: stages IVA · IVB
Lip
If cancer is in the lip, treatment may include surgery and external radiation therapy with or without internal radiation therapy.
Sources: external radiation therapy · internal radiation therapy
Front of the tongue
If cancer is in the front of the tongue, treatment may include:
surgery to remove the tongue and sometimes the larynx (voice box) with or without radiation therapy
Sources: larynx · radiation therapy
radiation therapy as palliative therapy to relieve symptoms and improve quality of life
Sources: palliative therapy · symptoms · quality of life
Buccal mucosa
If cancer is in the buccal mucosa (the lining of the inside of the cheeks), treatment may include surgery (wide local excision) and/or radiation therapy.
Sources: buccal mucosa · wide local excision · radiation therapy
Floor of the mouth
If cancer is in the floor (bottom) of the mouth, treatment may include surgery before or after radiation therapy.
Sources: radiation therapy
Lower gingiva
If cancer is in the lower gingiva (gums), treatment may include surgery and/or radiation therapy.
Sources: gingiva · radiation therapy
Retromolar trigone
If cancer is in the retromolar trigone (the small area behind the wisdom teeth), treatment may include surgery to remove the tumor, lymph nodes, and part of the jawbone, followed by radiation therapy.
Sources: retromolar trigone · wisdom teeth · lymph nodes · radiation therapy
Upper gingiva or hard palate
If cancer is in the upper gingiva (gums) or hard palate (the roof of the mouth), treatment may include surgery with radiation therapy.
Sources: gingiva · hard palate · radiation therapy
Lymph nodes
For cancer that may have spread to lymph nodes, treatment may include radiation therapy and/or surgery (neck dissection).
Sources: lymph nodes · radiation therapy · neck dissection
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Lip and Oral Cavity Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Learn about the treatments listed below in the Treatment Option Overview.
Sources: Treatment Option Overview
Treatment of metastatic (IVC) and recurrent lip and oral cavity cancer may include:
Sources: metastatic · IVC · recurrent
surgery, if radiation therapy was used before
Sources: radiation therapy
surgery and/or radiation therapy, if surgery was used before
immunotherapy (nivolumab or pembrolizumab)
Sources: immunotherapy · nivolumab · pembrolizumab
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Head and Neck Squamous Cell Cancer
ClinicalTrials.gov recordRecurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
ClinicalTrials.gov recordHead and Neck Cancer
ClinicalTrials.gov recordHead and Neck Cancer
ClinicalTrials.gov recordStage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV...
ClinicalTrials.gov recordRecurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent...
ClinicalTrials.gov recordStage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III...
ClinicalTrials.gov recordNeck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous...
ClinicalTrials.gov recordNausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and...
ClinicalTrials.gov recordMetastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity, Metastatic...
ClinicalTrials.gov recordStage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III...
ClinicalTrials.gov recordRecurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous...
ClinicalTrials.gov recordKaposi´s Sarcoma
ClinicalTrials.gov recordChemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III...
ClinicalTrials.gov recordRecurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous...
ClinicalTrials.gov recordRecurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell...
ClinicalTrials.gov recordMucositis, Oral Complications, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Lymphoepithelioma of the Nasopharynx,...
ClinicalTrials.gov recordRecurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous...
ClinicalTrials.gov recordClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal...
ClinicalTrials.gov recordLip, Oral Cavity Squamous Cell Carcinoma, Pharynx, Larynx, Squamous Cell Carcinoma
ClinicalTrials.gov recordClinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma...
ClinicalTrials.gov recordClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head...
ClinicalTrials.gov recordStage IVC Lip and Oral Cavity Cancer AJCC v8
Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7